NCT05441501View on ClinicalTrials.gov

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

March 26, 2024

Study Completion Date

March 31, 2024

Conditions
Prostatic Neoplasms
Interventions
DRUG

JNJ-80038114

JNJ-80038114 will be administered.

Trial Locations (6)

19107

Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia

37203

Sarah Cannon Research Institute, Nashville

55455

University Of Minnesota, Minneapolis

NW1 2PG

University College London Hospitals NHSFT, London

M20 4BX

The Christie NHS Foundation Trust Christie Hospital, Manchester

SM2 5PT

Royal Marsden Hospital, Sutton

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY